Can cycle day 7 FSH concentration during controlled ovarian stimulation be used to guide FSH dosing for in vitro fertilization? by Yaakov Bentov et al.
Bentov et al. Reproductive Biology and Endocrinology 2013, 11:12
http://www.rbej.com/content/11/1/12RESEARCH Open AccessCan cycle day 7 FSH concentration during
controlled ovarian stimulation be used to guide
FSH dosing for in vitro fertilization?
Yaakov Bentov1,2,3*, Eliezer Burstein1,2,3, Courtney Firestone2,3, Ross Firestone2,3, Navid Esfandiari1,2
and Robert F Casper1,2,3Abstract
Background: When stimulating a patient with poor ovarian response for IVF, the maximal dose of gonadotropins
injected is often determined by arbitrary standards rather than a measured response. The purpose of this study was
to determine if serum FSH concentration during an IVF stimulation cycle reflects follicular utilization of FSH and
whether serum FSH values may inform dose adjustments of exogenous FSH.
Methods: In this retrospective cross sectional study we studied 155 consecutive IVF cycles stimulated only with
recombinant human FSH. We only included long GnRH agonist protocols in which endogenous FSH levels were
suppressed. We correlated the serum concentration of cycle day (CD) 7 FSH with the number of oocytes retrieved,
cleaving embryos and pregnancy rate.
Results: We found that a CD7 FSH concentration above 22 IU/L was associated with poor response regardless of
the daily dose of FSH injected and a lower pregnancy rate.
Conclusions: We concluded that CD7 FSH concentration during stimulation could be used to guide FSH dosing in
poor responders. If the CD7 FSH concentration is above 22 IU/L increasing the dose of FSH in an attempt to recruit
more growing follicles is unlikely to be successful.
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stimulationBackground
The stimulation of ovarian follicular development is an es-
sential part of in vitro fertilization (IVF) and has a major
impact on the treatment outcome. Over the years multiple
protocols for ovarian stimulation have been developed
containing different combinations of gonadotropins, GnRH
analogues and other adjuvants [1-3]. Despite the differences
between protocols it is clear that the major component re-
sponsible for follicular maturation is follicle stimulating
hormone (FSH) [4]. Furthermore a direct dose response re-
lationship between amount of FSH administered and fol-
licle recruitment and growth has been described [5].* Correspondence: ybentov@tcart.ca
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reproduction in any medium, provided the orTypically, stimulation for IVF would involve daily subcuta-
neous injections of recombinant or urinary-derived FSH
usually at a constant daily dose for 10–13 days.
Poor ovarian response may be defined as a low oocyte
yield despite treatment with a high dose of FSH [6]. Poor
ovarian response is one of the main obstacles to preg-
nancy success in IVF since treatment is dependent on
the quantity as well as the quality of oocytes and
embryos. Since poor ovarian response involves resistance
to the action of FSH, one way to improve response is to
increase the daily dose of FSH administered. This prac-
tice potentially allows follicles with fewer FSH receptors,
and requiring a higher FSH threshold, to respond to the
stimulation. However, since the only parameter currently
used to adjust the dose of FSH is ovarian response, and
since injectable FSH preparations are still quite expen-
sive, it would be valuable to have an early prospectiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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useful or not. Also, the concept of “the maximal” daily
dose of FSH given to a poor responding patient is
dependent mostly on clinic policy without any objective
tools to guide the decision.
Factors other than the daily dose of FSH may affect
the serum concentration of FSH. The measured serum
concentration represents the balance between the rate of
absorption and the rate of elimination of FSH. With
consecutive daily administration of FSH, steady state
levels are thought to be reached after 3–5 days of treat-
ment [7]. Endogenous FSH and exogenous FSH with
altered patterns of glycosylation have different rates of
elimination [8]. Urinary derived FSH contains a higher
proportion of acidic isoforms and as a result is
characterized by a slower clearance rate and lower bio-
activity relative to recombinant FSH [8]. Moreover,
stimulation cycles that include down regulation of the
pituitary secretion of endogenous FSH show an
increased exogenous FSH Cmax [5]. Another mechan-
ism by which FSH is cleared from the circulation
involves binding to its receptor [9]. This could explain
why the more bioactive form of FSH is also cleared
faster [8]. We speculated that women with a poor ovar-
ian response would have a lower number of follicles that
may contain few FSH receptors, and as a result would
show a lower rate of FSH clearance and a higher steady
state serum FSH concentration compared to good
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Characteristics of the patients included in the study. For each parameter we describ
and the standard error of the mean.concentration of FSH during ovarian stimulation could
provide information on whether exogenous FSH is being
utilized efficiently. The objective of the present study
was to correlate serum FSH concentrations in the early
phase of ovarian stimulation with the number of oocytes
retrieved, embryo development and pregnancy outcome.
Methods
To test our hypothesis, we conducted a retrospective cross-
sectional study that included all IVF cycles conducted at
the Toronto Center for Advanced Reproductive Technol-
ogy (TCART) between January 2008 and May 2012 that
met the following inclusion criteria.
 Long mid luteal GnRH agonist down regulation
protocol
 Only recombinant FSH was used for ovarian
stimulation
 The daily dose of recFSH was 200–300 international
units a day.
Exclusion criteria were:
 Cycles that were cancelled prior to oocyte retrieval
 Missing data on baseline FSH concentration and on
cycle day 7 as well as the number of oocytes,
embryos or outcome.
 Incomplete down regulation (CD3 FSH ≥ 10 or CD3
Estradiol ≥ 200 pmol/L)ian Range Standard deviation SEM
21-45 3.61 0.294
.5 17-41 4.78 0.74
2.4-20 3.08 0.469
e, the average, median, range, standard deviation, number of observations
Figure 1 CD3 & CD7 FSH and recFSH dose. Serum FSH
concentration on cycle day 3 and 7 (primary Y axis) and average
starting daily dose of recFSH (secondary Y axis) in the different
age groups.
Bentov et al. Reproductive Biology and Endocrinology 2013, 11:12 Page 3 of 6
http://www.rbej.com/content/11/1/12The search of patient data was approved by the Mount
Sinai Hospital institutional ethics committee. FSH used by
patients in the study was recombinant FSH (Gonal-FW
Serono, Oakville, Ontario, Canada or PuregonW, Merck,
Scarborough, Ontario, Canada). We administered
10,000 IU of hCG as a single subcutaneous injection (human
chorionic gonadotropin, PregnylW, Merck, Scarborough,
Ontario, Canada) 36 hours before egg retrieval when at least
two follicles measured 18 mm in diameter. All cycles
received luteal phase support with progesterone in the form
of vaginal suppositories (Kingsway Drugs, Toronto, Ontario,
Canada) 200 mg three times daily. The long luteal protocol
involved downregulation with a GnRH agonist, buserelin
acetate (Suprefact, Sanofi-Aventis Canada Inc) started about
one week before menses and stimulation with recFSH was
started on day 3 (CD3) of the next cycle and continued until
the administration of the hCG trigger injection. In these
cycles patients were seen on cycle day 3 for a blood test
(estradiol and FSH) and ultrasound and again on cycle day
7 (CD7). Between these days the patient was self-
administering the medication and no changes were made to
dose.
Analysis of FSH serum concentration was done using
the Vitros ECiQ Immunodiagnostic System (Ortho-Clin-
ical diagnostics, Johnson and Johnson, Rochester, NY
14626–5101). The analytical sensitivity of this assay is typ-
ically 0.50 IU/L. The intra-assay variability was 1.7-2.8%
and inter-assay variability was 3.7-10.6%.
Statistical analysis was done using GraphPad statistical
analyzer. Due to a non-normal distribution, non-parametric
tests were used (Kruskal-Wallis test) to test the significance
of continuous parameters and Fisher’s exact test for bino-
mial parameters. The correlation between serum FSH on
cycle day 7 and the dose of FSH administered was compared
using one way ANOVA test. A p-value of ≤0.05 was
considered as significant.Results
We were able to identify 155 cycles within the period of
time between January 2008 and May 2012 that met all of














The distribution of the different starting doses of RecFSH and their
corresponding CD7 serum FSH.Patient characteristics are detailed in Table 1. The
average age of patients included in the study was 35.8 -
years (21–45), Average BMI was 24.5 (17–41) and base-
line CD3 FSH was 6.5 (2.4-20) prior to the IVF cycle.
Late maternal age (37 and older) accounted for 44.5% of
the patients; male factor infertility was associated with
56% of the cycles and tubal factor in 23.1% (Table 1). All
cycles included in the study were of the long mid luteal
GnRH agonist down-regulation protocol with recFSH
only used for ovarian stimulation. The average daily dose
of recFSH administered was 250.3 IU (200–300 IU). The
increase in dose of recFSH is typically done in
increments of 25 IU and therefore was not regarded as a
continuous variable. The distribution of the different
starting doses of RecFSH is presented in Table 2. The
serum concentration of CD7 FSH for the 4 daily FSHFigure 2 CD7 serum FSH in relation to age. XY graph showing
serum FSH concentration on CD7 according to the patient’s age.
Figure 4 CD7 FSH and embryo yield. Embryo yields with different
thresholds of serum FSH on CD7 to define a high level starting with
a threshold of > 5 IU/L until 30 IU/L. Error bars indicate the standard
error of the mean.
Table 3 IVF cycle characteristics
Average Median Range Standard
deviation
SEM
CD3 FSH (IU/L) 5.0 4.9 0.15-9.5 1.53 0.131
CD3 Estradiol
(pmol/L)
98.3 92.4 3-200 39.9 3.31
CD3 LH (IU/L) 3.8 3.4 0.1-12.2 2.45 0.21
Dose of FSH (IU) 249.6 250 200-300 44.05 3.12




9,862.2 8,639 567.8-36,571 7,066.3 624.6
The characteristics of all cycles included in the study (CD3 – cycle day 3).
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spectively (Figure 1 and Table 2). With GnRH agonist
downregulation there was no difference in day 3 FSH
concentrations in the stimulation cycles (Figure 1). Des-
pite the trend for an increased serum FSH with a higher
dose of injected FSH the differences using one way
Anova was not significant (pValue = 0.0502).
The correlation between the age of the patients and CD7
serum FSH was analyzed with Pearson’s correlation and was
found to be non-significant (R square 0.016 and p Value =
0.089) (Figure 2). Cycle characteristics are described in
Table 3.
Figure 3 describes the correlation between different
thresholds of serum FSH on cycle day 7 and the
corresponding oocyte yield. The thresholds examined
start with a serum FSH concentration of more than
5 IU/L and up to > 30 IU/L. The average oocyte yield
was 13.7 for the lowest threshold and 2 for the highest.
Correlation analysis using the Spearman analysis was
significant with a p Value <0.0001 (r = −0.9863).Figure 3 CD7 FSH and oocyte yield. Oocyte yields with different
thresholds of serum FSH on CD7 to define a high level starting with
a threshold of > 5 IU/L until 30 IU/L. Error bars indicate the standard
error of the mean.Figure 4 describes the correlation between CD7 serum
FSH concentration and the yield of embryos. Here we
used the same thresholds of more than 5 and up to
>30 IU/L. Mean embryo yield for the lowest threshold
was 8.11 and zero for the highest. Spearman analysis
showed a significant correlation with a p Value <0.0001
(r = −0.9803).
Figure 5 describes the association of pregnancy rate
with different thresholds of CD7 FSH. The pregnancy
rate for a CD7 FSH > 5 was 41.2% and went down to
zero with a CD7 FSH threshold > 23 IU/L. The figure
also shows the linear regression line and the 95%Figure 5 CD7 FSH and pregnancy rate. Pregnancy rates with
different thresholds of serum FSH on CD7 to define a high level
starting with a threshold of > 5 IU/L until 30 IU/L. The figure also
describes the linear regression line as well as the 95% confidence
interval range.
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0.3016 and the p value <0.01.
Discussion
Unlike many expensive medical treatments that are covered
by health insurance, infertility treatment is usually paid for
out of pocket. A recent publication estimated the median
cost of an IVF cycle in the United States at $24,373, with the
cost of an unsuccessful IVF treatment even higher ($25,921)
[10]. A significant portion of the total cost of IVF is spent
on gonadotropin injections. This observation is especially
true in poor responders who are usually treated with high
daily doses of FSH, at times exceeding 600 IU a day. Unfor-
tunately, after several days of injections and a few thousand
dollars spent on fertility drugs, the cycle may be cancelled
for lack of adequate response, or oocyte retrieval will be
pursued with less than the desired yield of oocytes.
In the present study, we show that a significantly
higher concentration of serum FSH following adminis-
tration of exogenous FSH did not result in a higher
number of oocytes and embryos. The administration of
similar doses of FSH resulted in a wide range of serum
FSH concentrations (6.8-36 IU/L) on CD 7 that nega-
tively correlated with oocyte yields. The steady state of
any substance in the serum represents its rate of intake
and clearance. In our clinic we see the patients on CD3
when they start gonadotropin administration and again
on day 7. In between these days the patients are not
monitored and no changes are made to the dose of
gonadotropins. These five days between the start of go-
nadotropin injections and the next measurement of its
serum concentration is the time in which injected
gonadotropins were shown to reach a steady state. Des-
pite the lack of significance, it is clear that there is a cor-
relation between the injected dose of FSH and its serum
concentration. However, the narrow range of daily FSH
dose,(200–300 IU a day) was associated with a much
wider range of serum FSH concentrations, with the
highest concentrations being 6 fold greater than the
lowest. This observation suggests that the rate of FSH
clearance plays an important role in its serum concen-
tration. This study is retrospective and, therefore, pos-
sibly subject to unrecognized biases. In order to reduce
the impact of age on endogenous FSH concentrations,
we only included cycles with a long mid luteal GnRH
agonist protocol in order to reduce the contribution of
endogenous FSH as much as possible. As seen in
Figure 1, the cycle day 3 FSH concentration was similar
in all 4 age groups (average of 5 IU/L) after pituitary
downregulation by GnRH agonist. Moreover, only cycles
with recFSH were included in order to prevent
differences in the rate of clearance that are attributed to
difference in acidic isoforms between recFSH and urin-
ary gonadotropins [8]. Although long luteal protocolsare considered to be overly suppressive for some older
patients, we felt that the use of this protocol was the
only way to eliminate the endogenous FSH differences
between groups that would preclude any meaningful in-
terpretation of the data.
In our study, serum concentration of FSH on CD7
showed a significant negative correlation with oocyte
and embryo yield, as well as pregnancy rates despite the
administration of a similar dose of FSH. The changes in
serum FSH concentration on CD7 cannot be attributed
to the baseline FSH or to the patient’s age since both did
not show a significant correlation.
At least part of the process of clearance of FSH from
the circulation involves binding of FSH to its receptor
and internalization of the hormone receptor complex.
Therefore, a low number of follicles containing FSH
receptors on granulosa cells will inevitably result in the
accumulation of FSH in circulation as a result of less
binding of FSH to FSHR [9].
We observed that the serum FSH concentration on CD7
predicted response to FSH administration with a dramatic
change in oocyte retrieval numbers and pregnancy outcome
above a serum FSH concentration of 22 IU/L. Our results
demonstrate that there was excessive circulating FSH in
poor responders and suggest that increasing the dose of
FSH would not be helpful since the FSH administered
already was not being completely used. This observation is
consistent with our clinical experience that doses of FSH
above 300 IU per day are unlikely to increase follicular re-
sponse in older women or previous poor responders, and
only adjunctive measures are likely to be of help in increas-
ing oocyte yield. These include sensitizing the follicles using
androgens prior to ovarian stimulation [11] or by adding LH
or hCG to recFSH during ovarian stimulation [12]. Alterna-
tively, if the FSH serum concentration on CD7 is less than
22 IU/L, there may be a place for increasing FSH dose if fol-
licular response is less than desired.
Conclusions
In conclusion, the only parameter currently used to
guide the choice of FSH dosing is the response of the
ovary, i.e. follicular development and estrogen produc-
tion. However, with poor response, it is difficult to de-
cide whether the dose of FSH should be increased.
Using a cut-off of 22 IU/L of serum FSH on CD7 may
provide a simple tool to guide this decision.
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